美股大专生
2019-03-11
$Seres Therapeutics, Inc.(MCRB)$ 新药通过了？
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
roy081231
2019-03-11
roy081231
这票的利好 是阿斯利康独家合作2000万美元三年注入，研究微生物抗癌。
什么也没有了～
APP内打开
发表看法
1
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":423286,"tweetId":"423286","gmtCreate":1552314407517,"gmtModify":1704792296329,"author":{"id":3483670833154473,"authorId":3483670833154473,"authorIdStr":"3483670833154473","name":"美股大专生","avatar":"https://static.tigerbbs.com/ea23ee2aeacb09cff59b79b67c5978a3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>$Seres Therapeutics, Inc.(MCRB)$ 新药通过了？</p></body></html>","htmlText":"<html><head></head><body><p>$Seres Therapeutics, Inc.(MCRB)$ 新药通过了？</p></body></html>","text":"$Seres Therapeutics, Inc.(MCRB)$ 新药通过了？","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/423286","repostId":0,"isVote":1,"tweetType":1,"viewCount":1818,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["MCRB"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":41,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":1383630,"gmtCreate":1552315725553,"gmtModify":1552315725553,"authorId":3463304378987174,"author":{"id":3463304378987174,"authorId":3463304378987174,"name":"roy081231","avatar":"https://static.tigerbbs.com/bdb39bd042ca955a4cb65c5ef11ccb0b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":423286,"type":1,"supId":0,"prevId":0,"content":"这票的利好 是阿斯利康独家合作2000万美元三年注入，研究微生物抗癌。","text":"这票的利好 是阿斯利康独家合作2000万美元三年注入，研究微生物抗癌。","html":"这票的利好 是阿斯利康独家合作2000万美元三年注入，研究微生物抗癌。","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/423286"}
精彩评论